



2026 Investor Presentation



Disclaimer

Forward-Looking Statements

All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward looking statements speak only as of the date of this report. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as the impact of widespread health emergencies, such as COVID 19 and respiratory syncytial virus, that may cause our results, activity levels, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements. Forward-looking statements may include, among other things, statements relating to: our ability to achieve or sustain profitability in the future; our ability to raise additional capital to fund our existing commercial operations, develop and commercialize new products and expand our operations; our ability to commercialize our products in development and to develop and commercialize additional products through our research and development efforts, and if we fail to do so we may be unable to compete effectively; our ability to generate sufficient revenue from the commercialization of our products to achieve and sustain profitability; our ability to comply with extensive government regulation and oversight both in the United States and abroad; our ability to maintain and expand our network of third-party independent sales agencies and distributors to market and distribute our products; and our ability to protect our intellectual property rights or if we are accused of infringing on the intellectual property rights of others; We cannot assure you that forward-looking statements will prove to be accurate, and you are encouraged not to place undue reliance on forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations expressed or implied by the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in our quarterly report, in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on March 4, 2026, and in other reports filed with the SEC that discuss the risks and factors that may affect our business. Other than as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, events or circumstances occurring after the date of this quarterly report.

Use of Non-GAAP Financial Measures

This presentation includes certain non-GAAP financial measures, such as free cash flow, adjusted diluted (loss) earnings per share and Adjusted EBITDA, which differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). Free cash flow, which we reconcile to “Net cash used in operating activities” is cash flow from operations increased by “Capital expenditures”. Adjusted loss per share in this press release represents diluted loss per share on a GAAP basis, plus the accreted interest attributable to acquisition installment payables, restructuring charges, tariffs, European Union Medical Device Regulation fees increase, acquisition related costs, and minimum purchase commitment costs. We believe that providing the non-GAAP diluted loss per share excluding these expenses, as well as the GAAP measures, assists our investors because such expenses are not reflective of our ongoing operating results. Adjusted EBITDA in this release represents net loss, plus interest expense, net plus other income, income tax charge (benefit), depreciation and amortization, stock-based compensation expense, restructuring charges, European Union Medical Device Regulation fees increase, acquisition related costs, and the cost of minimum purchase commitments. The fair value adjustment of contingent consideration is associated with our estimates of the value of earn-outs in connection with certain acquisitions. The Company believes the non-GAAP measures provided in this earnings release enable it to further and more consistently analyze the period-to-period financial performance of its core business operating performance. Management uses these metrics as a measure of the Company’s operating performance and for planning purposes, including financial projections. The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. Free cash flow is a non-GAAP financial measure and has limitations because it does not represent the cash flow available for management’s use as it does not reflect capital expenditures which will likely recur in the future. Adjusted EBITDA is a non-GAAP financial measure and should not be considered as an alternative to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and it should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, the measure is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as debt service requirements, capital expenditures and other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and other potential cash requirements. In evaluating these non-GAAP measures, you should be aware that in the future the Company may incur expenses that are the same or similar to some of the adjustments in this presentation. The Company’s presentation of non-GAAP free cash flow, diluted loss per share or Adjusted EBITDA should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using these adjusted measures on a supplemental basis. The Company’s definition of these measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation. The schedules below contain reconciliations of Net cash used in operating activities to Free cash flow (Non-GAAP), GAAP diluted loss per share to non-GAAP diluted loss per share and net loss to non-GAAP Adjusted EBITDA.




OrthoPediatrics was founded on the **cause** of impacting the lives of children with orthopedic conditions

+ 1,382,000

pediatric patients treated since inception¹

Re-Purposed Adult Plate

Screws through growth plate



- 01 Children's **unique clinical conditions**
- 02 Existing solutions are **re-purposed from adult implants**
- 03 Limited development of **new technologies**
- 04 No **specialized sales force** in Pediatric Orthopedics
- 05 Limited industry support of clinical **education**

PediLoc Femur

Screws parallel to growth plate



- 01 **Product development focused** exclusively on pediatric patients
- 02 **Broadest pediatric specific portfolio** in the industry
- 03 Delivering first in market **novel surgical solutions**
- 04 Only global **commercial channel to market**
- 05 Leading provider of surgeon **clinical education**

- ✓ Enhance surgeon confidence
- ✓ Increase surgical efficiency
- ✓ Improve surgical accuracy



Innovative Technology

+90 unique pediatric systems

Consistent **cadence** of innovative product launches

Expanding suite of **enabling** technologies

Internal **R&D**, acquisitions, and partnerships



Commercial Execution

Only global sales & distribution channel

Serve **100% of top children's hospitals** in the U.S.

~240 domestic field representatives

Sell in **over 75** countries around the world



Clinical Education

Commitment to clinical education

Leading **sponsor** of critical pediatric medical societies


>700 clinical product/education events per year

Founder of Foundation of Advancing Pediatric Orthopedics

**Consistent
YoY
Growth
Since Inception¹**

Total Global **Addressable Market** – **\$6.2B**

U.S. Addressable Market¹ — \$2.8B



Competitive Dynamics

- 01 Large incumbents repurpose adult implants
- 02 Require specialized sales force
- 03 Lack of focus on pediatric conditions



01



Laser focus on high-volume Children's Hospitals that treat majority of pediatric patients

02



Provide a **broad product portfolio** uniquely designed to treat children, surround pediatric orthopedic surgeons covering their needs

03



Deploy instrument sets and provide unparalleled sales support

04




Expand addressable market through aggressive investment in **R&D and select M&A opportunities**

05



Train next generation of pediatric orthopedic surgeons


Current U.S. Target Market¹ — \$1.6B



Comments

- 01 ~1,520 Fellowship Trained Pediatric Surgeons
- 02 Majority of Pediatric Centers are Teaching Hospitals
- 03 Centers Treat Most Complex Pediatric Conditions
- 04 ~80% of Pediatric Surgeons time is Non-Surgical


20 Years of Foundation Building



90+ Systems

Broadest Portfolio across:

Trauma & Def
Scoliosis
Sports Med
External Fixation
Specialty Bracing
Enabling Tech



Surgeon-led Innovation

- New products originate from unmet clinical needs identified by pediatric orthopedic surgeons

Building Platforms

- Focus on platform & product family development rather than isolated products

Multi-year super cycle

- Entered a multi-year product super cycle, with multiple launches expected over several years

Strong Innovation & R&D

Trauma & Deformity

3P™ Small | Mini

PNP | Retro

3P™ | Knee

PNP | SD

Pin to Bar Ex-Fix

Scoliosis

VerAxis™ Scoliosis

eLLi™

OPSB

Tractor Fix

Enabling Tech

Predictive Planning

Entering a “Super-Cycle” of Differentiated Product Launches




Entering a “Super-Cycle” of Differentiated Product Launches



Total Revenue (\$M)

+20% CAGR



Accelerating Sales Growth Post-IPO Through Strategic Investment and Innovation

	2016	2025	CAGR
U.S. Independent Sales Consultants	90	232	11%
Instrument Set Deployments	\$7M	\$17	10%
Unique Pediatric Systems	17	87	20%
Intl. Independent Sales Agencies	0	16	Fav



Accelerate Revenue Growth



Increase Hospital Penetration




Improve Profitability



Leverage Balance Sheet

Set Deployment Efficiencies

Reducing set deployments as a percentage of revenue while continuing to take share



¹ Boston O&P Acquisition

² Represents the midpoint of the Company's 2026 revenue guidance range of \$265.0 to \$269.0 million and expected annual set deployment

Improving ROI on Sets Deployed

01

Super Cycle Product Launches

- Products with defined clinical needs & stronger financial profile (higher ASPs and gross margins, less capital required)

02

Higher Utilization

- Market share gains and ramping in utilization of previous deployments creates leverage

03

Platform Systems

- Systems designed to utilize similar parts produces platform synergies and capital efficiencies

Partnership

Acquisition



2017

2019

2020

2021

2022

2023

2024

2026





**Aggressive market-based
clinic expansion strategy**

18 new markets by 2027
(27 total)



**Accelerate R&D with
increasing number of YoY
launches**

Launch 4 products in 2024
and 5 in 2025



**Scale OPSB selling channel
and sales force – grow with
current portfolio of
products**

Doubling size of the sales
channel

Pace of Market Expansion



+4 markets
in 2025

+6 markets
in 2026


+8 markets
in 2027

**OPSB clinics
expected to be in 27
territories in 2027
out of 80
target territories**

	Greenfield	Acqui-Hire
Initial Investment	\$200k-\$500k	\$500K-\$1M
EBITDA Goal	Positive EBITDA by end of first full year	Positive EBITDA by end of first full year
FCF Goal	After first full year	Within first year
ROI Goal	Break even ROI by Year 3	Break even ROI by Year 5
Time to Ramp	6 months for licensure, insurance, lease, clinicians, training, etc.	Immediate licensure, insurance, location, clinicians, training etc.
IRR	40%	25%

**1-4
Clinics
per
market
expected**

U.S. Potential Target Market ¹ — \$1.0B



**Levity Device
for Gait Assist**



**Dynamic Femur
Fracture (DF2)
Brace**

Supporting more than 20 fellowships

01

OP Hands-on sales training and support

- Annually invests 3% of sales on clinical education
- Conducts >700 product/training sessions per year

02


Market development

- Fosters early relationships with young surgeons and fellows to drive sustainable growth

03

Continuous education

- Major Sponsor of the prominent pediatric orthopedic societies







Trauma & Deformity

Pediatric Systems

Revenue




70% of Revenue



Scoliosis

Pediatric Systems


Revenue



28% of Revenue




2025 Revenue by Product Family




- Trauma & Deformity
- Scoliosis
- Sports Medicine

Strong History of Y/Y Growth (\$M)



¹ Impacted by COVID ² Represents the midpoint of the Company's 2026 revenue guidance range of \$265.0 to \$269.0 million

Seasonality Drives Stronger Performance in Summer Months and Holiday Periods



(\$ in Millions)

Income Statement Summary

	FY2023	FY2024	FY2025
Revenue	\$148.7	\$204.7	\$236.3
Growth %	22%	38%	15%
Gross profit	\$111.3	\$148.6	\$172.7
Margin %	75%	73%	73%
Operating expenses	\$138.0	\$183.6	\$211.9
Operating loss	(\$26.8)	(\$35.0)	(\$39.2)
Net (loss) income	(\$21.0)	(\$37.8)	(\$39.6)
EPS diluted	(\$0.92)	(\$1.64)	(\$1.69)

2Q 2025	2Q 2026
\$61.1	\$70.5
16%	15%
\$44.0	\$52.4
72%	74%
\$54.7	\$56.4
(\$10.7)	(\$4.1)
(\$7.1)	(\$7.2)
(\$0.30)	(\$0.30)

(\$ in Millions)


Adjusted EBITDA Reconciliation

	Three Months Ended June 30,	
	2025	2026
Net loss	(\$7.1)	(\$7.2)
Interest expense, net	1.1	2.5
Other expense (income), net	(4.7)	0.3
Income tax charge	-	0.3
Depreciation and amortization	5.1	5.7
Stock-based compensation	5.3	4.2
Restructuring charges	3.0	-
Tariffs	0.6	0.2
Acquisition related costs	0.5	0.8
Minimum purchase commitment cost	0.3	-
Adjusted EBITDA	\$4.1	\$6.8

	Three Months Ended June 30,	
	2025	2026
Loss per share, diluted (GAAP)	(\$0.30)	(\$0.30)
Tariffs	0.03	0.01
Restructuring charges	0.13	-
Acquisition related costs	0.02	0.03
Minimum purchase commitment cost	0.01	-
Adjusted loss per share, diluted (non-GAAP)	(\$0.11)	(\$0.26)


Free Cash Flow (\$M)

Total Year



■ Cash Used For Working Capital
■ Sets Deployed
■ Adj. EBITDA

Quarterly



■ Cash Used For Working Capital
■ Sets Deployed
■ Adj. EBITDA

YTD



■ Cash Used For Working Capital
■ Sets Deployed
■ Adj. EBITDA

(\$ in Millions)
As of June 30, 2026

Assets	
Cash, cash equivalents & short-term investments	\$47.9
Accounts receivable	61.0
Inventory (net)	137.6
Other current assets	6.1
Total Current Assets	252.5
PP&E (net)	48.6
Intangibles and goodwill	210.3
Total Assets	\$511.4

Liabilities	
Accounts payable	\$22.2
Debt	99.6
Accrued comp. & other liab.	41.8
Acquisition pay. & cont. consideration	4.1
Paid-in capital	633.4
Accumulated deficit (net)	(293.1)
Accumulated other comprehensive loss	3.2
Total Liabilities / Equity	\$511.4

(\$ in Millions)

Full Year 2026 Guidance

2026 Guidance

	FY2026
Revenue	\$265.0 to \$269.0
Adjusted EBITDA	~\$25.0
Free Cash Flow	Breakeven

Assumptions

	FY2026
2026 Total Revenue Growth %	12% to 14%
Set Deployment	~\$10.0



- 01 Only diversified company focused exclusively on pediatric orthopedics
- 02 Large, underpenetrated market opportunity in pediatrics
- 03 Highly concentrated customer base with targeted commercial strategy
- 04 Broad product portfolio with innovative solutions
- 05 Only provider committed to pediatric clinical education
- 06 Dynamic, award-winning corporate culture
- 07 Proven commercial execution and attractive financial profile



2850 Frontier Drive • Warsaw, IN 465852
ph: 574.268.6379 or 877.268.6339
fax: 574.268.6302
www.OrthoPediatrics.com